ADMA BiologicsADMA 64 Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $17.93 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 147 Biotechnology companies, ADMA Biologics ranks worse than 680271.43% on this metric.
As of today (2026-06-24), the Forward Annual Dividend Yield of ADMA Biologics is 0.00%.
As of today (2026-06-24), the Trailing Annual Dividend Yield of ADMA Biologics is 0.00%.
ADMA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
ADMA Biologics Forward Dividend Yield % Related Terms
ADMA vs ZYME, NRIX, IOVA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, ADMA Biologics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
ADMA Biologics (ADMA) has a Forward Dividend Yield % of 0.00% as of Jun. 24, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #999999 out of 147 companies in the Biotechnology industry.
Is ADMA Biologics' Forward Dividend Yield % too high?
ADMA Biologics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, ADMA Biologics ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Forward Dividend Yield % compare to ZYME and NRIX?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #999999 out of 147 companies for Forward Dividend Yield %. This places ADMA Biologics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.93, compared to a current price of $8.69 — trading 51.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.69 is trading 51.6% below its estimated GF Value™ of $17.93.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Forward Dividend Yield %: 0.00%
GF Value™: $17.93 vs. price of $8.69 (51.6% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 